NeuroSense Therapeutics
paradigm trial demonstrates safety and tolerability achieving primary | NeuroSense Therapeutics
Company
Deck Type
Sector
Industry
Deck date
October 2024
Slide
14 of 27
Related slides by other companies
ATAI
Investor Presentation
March 2023
phase proof of concept trial design all subjects tid tid placebo trial status in data anticipated randomized week study of and patients with | ATAI
Apollomics
SPAC
September 2022
| Apollomics
MindMed
Investor Presentation
November 2024
phase gad part schematics extension phase voyage a panorama | MindMed
ATAI
Investor Presentation
April 2023
phase proof of concept trial design all subjects tid tid placebo trial status in data anticipated randomized week study of and patients with | ATAI
Other recent decks by NeuroSense Therapeutics
See all presentations (4 decks)
Investor Presentation
January 2024
Investor Presentation
December 2023
Investor Presentation
June 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights